Pliant Therapeutics Q3 2020 Earnings Report
Key Takeaways
Pliant Therapeutics reported related party revenue of $4.8 million for the third quarter of 2020, compared to none for the prior-year quarter. Research and development expenses were $16.9 million, and net loss was $16.5 million. The company had cash, cash equivalents, and short-term investments of $294.0 million as of September 30, 2020.
Enrollment of PLN-74809 Phase 2a 12-week trials in IPF and PSC progressing.
Phase 2a PET imaging trial of PLN-74809 in IPF is enrolling.
Completed dosing of an extended Phase 1 dose escalation trial of PLN-74809 in healthy volunteers.
Phase 2a trial of PLN-74809 treatment of COVID-19 related ARDS has been initiated.
Pliant Therapeutics
Pliant Therapeutics
Pliant Therapeutics Revenue by Segment
Forward Guidance
Pliant believes it has sufficient funds to meet its operating and capital requirements into 2023.